Economic information and modeling report
Modeling overview
5 evidence topics · 4 sources
Summary: published economic evaluations, HTA status, and commercial forecasts
No published cost-effectiveness analysis, budget impact model, or health technology assessment of inaxaplin or of any other APOL1-targeted therapy was identified, and no ICER review was identified. A 2025 narrative review states that the cost-effectiveness of emerging APOL1-targeted therapies “remains uncertain”. The only APOL1-related economic analysis identified is a “crude cost analysis” of donor genotyping at one center, in which 1 of 26 potential African American living donors had a high-risk genotype. A GlobalData forecast published in 2024 projects U.S. inaxaplin revenue of $138 million in 2034. Guggenheim Securities analysts assigned a 65% probability of success in primary AMKD and 45% in the type 2 diabetes population; Vertex investor relations stated that AMPLITUDE could address about 150,000 people in the U.S. and Europe ; Fierce Biotech reported that an FDA label covering the two AMPLIFIED cohorts would add about 100,000.
Published cost-effectiveness analyses, budget impact models, and HTA reviews of inaxaplin
No evidence found.
Cost-effectiveness of emerging APOL1-targeted therapies
“At present, the cost-effectiveness of the aforementioned emerging therapeutic strategies remains uncertain.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“If similar pricing were applied to therapies for APOL1-mediated kidney disease, such intervention would be unaffordable in sub-Saharan Africa, the region bearing the highest disease burden.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote